Aspen Neuroscience, Inc. ya sanar da cewa a wannan watan za ta kaddamar da binciken gwajin gwajin marasa lafiya na farko irinsa, tare da yin aiki tare da wuraren binciken asibiti da yawa a Amurka.
Nazarin Ƙwararrun Ƙwararru na Gwaji na Kamfanin mataki ne na farko don shigar da aikace-aikacen Sabuwar Magunguna (IND) tare da Cibiyar Abinci da Magunguna ta Amurka don ANPD001, ɗan takararta na farko na ci gaban warkewa don yuwuwar maganin cutar Parkinson na idiopathic (PD). Nazarin Ƙwararrun Ƙwararru na Shirye-shiryen Gwaji zai ba da bayani ga da kuma tantance masu yuwuwar masu neman haƙuri don gwajin gwajin asibiti na farko na kamfanin na ANPD1 na Phase 2/001A. Kamfanin zai sanar da wurare masu yawa na Amurka a duk lokacin bazara.
"Wannan wani lokaci ne na tarihi ga marasa lafiya da kuma ƙungiyar Aspen Neuroscience, yayin da muke buɗe binciken mu na farko don ƙaddamar da binciken mu na iPSC da aka samu na maganin maye gurbin kwayar cutar ta Parkinson," in ji Damien McDevitt, Ph.D., shugaban kasa da shugaban. jami'in zartarwa. "Mun yi farin ciki da kuma ƙasƙantar da kai don fara wannan mataki na gaba yayin watan Fadakarwar Cutar Parkinson. Wannan babban ci gaba ne ga al'ummar marasa lafiya, ga masu ba da kiwon lafiya da kuma fannin ilimin jijiya."
PD ita ce cuta ta biyu da aka fi sani da neurodegenerative, tana shafar kusan Amurkawa miliyan ɗaya da fiye da mutane miliyan goma a duk duniya. Ko da tare da ma'auni na maganin kulawa na yanzu, marasa lafiya na iya haifar da matsalolin motsa jiki masu lalacewa saboda asarar kwayoyin dopamine a cikin kwakwalwa; kusan kashi 50% sun ɓace tun kafin ganewar asali.
Aspen Neuroscience shine babban kamfani wanda ke haɓaka maye gurbin kwayar halitta wanda zai iya kawar da buƙatar maganin rigakafi. Hanyar tana amfani da iPSCs na fata na majiyyaci don samar da maye gurbin dopamin neurons don dasawa baya cikin majiyyaci iri ɗaya. An haɓaka shi daga ƙwayar ƙwayar cuta mai sauƙi na fata, za a ƙididdige sel kowane majiyyaci don yuwuwar tasiri ta amfani da kayan aikin genomics na tushen AI, kafin a dasa su don amfanin asibiti.
